BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Receptor for advanced glycation endproducts (RAGE)

...in Phase III testing for Alzheimer's disease. Dynamis Therapeutics Inc. has the RAGE inhibitor DYN-15...
BioCentury | May 3, 2012
Distillery Therapeutics

Indication: Cancer

...antibodies against the specific RAGE domains involved in mediating metastasis. Dynamis Therapeutics Inc.'s RAGE inhibitor, DYN-15...
BioCentury | Mar 24, 2008
Clinical News

Dynamis preclinical data

...In aged rats, DYN-15 significantly decreased the Receptor for Advanced Glycations End (RAGE) products in kidney...
...RAGE inhibitor was orally administered for 32 weeks. Dynamis Therapeutics Inc. , Malvern, Pa. Product: DYN-15...
BioCentury | Mar 24, 2008
Clinical News

Dynamis preclinical data

...Mice given 3 escalating doses of DYN-15 in their drinking water showed dose-dependent increases in survival...
...an average of 256 days longer than controls. Dynamis Therapeutics Inc. , Malvern, Pa. Product: DYN-15...
Items per page:
1 - 4 of 4